



DIVERSIFIED BUSINESS MODEL DRIVING EXCEPTIONAL GROWTH

FULL-YEAR 2020 SALES WORLDWIDE

\$34.6
billion

+9.8%¹
on organic basis*

SALES PERFORMANCE ACROSS ABBOTT

 **\$11.8B**
MEDICAL DEVICES

 **\$10.8B**
DIAGNOSTICS

 **\$7.6B**
NUTRITION

 **\$4.3B**
ESTABLISHED
PHARMACEUTICALS

FULL-YEAR 2021 GUIDANCE ADJUSTED DILUTED EPS²

AT LEAST
\$5.00

REFLECTING GROWTH
OF MORE THAN
35% VERSUS
PRIOR YEAR

*Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated Jan. 27, 2021, available at www.abbottinvestor.com.

1. On a GAAP basis, full-year Abbott sales increased 8.5%. 2. Abbott projects full-year 2021 diluted earnings per share from continuing operations under GAAP of at least \$3.74, reflecting growth of at least 50% versus the prior year. Abbott forecasts specified items for the full-year 2021 of \$1.26 primarily related to intangible amortization, expenses associated with acquisitions, restructuring and cost reduction initiatives and other net expenses.